Crucell Cuts a Good Bargain
Executive Summary
J&J Centocor's deal with Crucell demonstrates how large pharma companies are being forced to make bigger sacrifices in return for potential products. Centocor is believed to be paying just $2 million, with $1-2 million in annual fees but the deal value could reach $100 million and give J&J an opportunity to strengthen its oncology product line. And Crucell gets closer to its goal of being a product company without taking on all the risks of drug development.
You may also be interested in...
Crucell Falls Back on Vaccines
Forced by a series of setbacks to downsize its antibody platform, Crucell is now turning to vaccine applications of its human cell production technology to satisfy its product developer ambitions.
J&J/Centocor: One Rx Treats a Range of Growth Ailments
Acquiring Centocor gives J&J products to help fill the void in its drug portfolio. Will it also use Centocor's core biologics expertise to launch a broader move into biotechnology?
EU Commission Wants Expert Opinion On Prostaglandin Analogs In Eyelash Growth Cosmetics
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Need a specific report? 1000+ reports available
Buy Reports